These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34950108)

  • 1. Discovery of a Positive Allosteric Modulator of Cholecystokinin Action at CCK1R in Normal and Elevated Cholesterol.
    Harikumar KG; Coudrat T; Desai AJ; Dong M; Dengler DG; Furness SGB; Christopoulos A; Wootten D; Sergienko EA; Sexton PM; Miller LJ
    Front Endocrinol (Lausanne); 2021; 12():789957. PubMed ID: 34950108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Basis of Action of a Small-Molecule Positive Allosteric Modulator Agonist at the Type 1 Cholecystokinin Holoreceptor.
    Desai AJ; Mechin I; Nagarajan K; Valant C; Wootten D; Lam PCH; Orry A; Abagyan R; Nair A; Sexton PM; Christopoulos A; Miller LJ
    Mol Pharmacol; 2019 Mar; 95(3):245-259. PubMed ID: 30591538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A type 1 cholecystokinin receptor mutant that mimics the dysfunction observed for wild type receptor in a high cholesterol environment.
    Desai AJ; Harikumar KG; Miller LJ
    J Biol Chem; 2014 Jun; 289(26):18314-26. PubMed ID: 24825903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity.
    Desai AJ; Henke BR; Miller LJ
    Bioorg Med Chem Lett; 2015 May; 25(9):1849-55. PubMed ID: 25862198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for positive allosteric modulators of cholecystokinin type 1 receptor potentially useful for management of obesity.
    Dengler DG; Sun Q; Harikumar KG; Miller LJ; Sergienko EA
    SLAS Discov; 2022 Oct; 27(7):384-394. PubMed ID: 35850480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of β-sitosterol on type 1 cholecystokinin receptor dysfunction induced by elevated membrane cholesterol.
    Desai AJ; Dong M; Miller LJ
    Clin Nutr; 2016 Dec; 35(6):1374-1379. PubMed ID: 27016394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target.
    Miller LJ; Desai AJ
    Trends Endocrinol Metab; 2016 Sep; 27(9):609-619. PubMed ID: 27156041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of cholesterol absorption is a mechanism for cholecystokinin-induced hypercholesterolemia.
    Zhou L; Yang H; Okoro EU; Guo Z
    J Biol Chem; 2014 May; 289(19):12989-99. PubMed ID: 24692543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholecystokinin-induced satiety, a key gut servomechanism that is affected by the membrane microenvironment of this receptor.
    Desai AJ; Dong M; Harikumar KG; Miller LJ
    Int J Obes Suppl; 2016 Dec; 6(Suppl 1):S22-S27. PubMed ID: 28685026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.
    Desai AJ; Lam PC; Orry A; Abagyan R; Christopoulos A; Sexton PM; Miller LJ
    J Med Chem; 2015 Dec; 58(24):9562-77. PubMed ID: 26654202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of ursodeoxycholic acid on a CCK1R cholesterol-binding site may contribute to its positive effects in digestive function.
    Desai AJ; Dong M; Harikumar KG; Miller LJ
    Am J Physiol Gastrointest Liver Physiol; 2015 Sep; 309(5):G377-86. PubMed ID: 26138469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesterol-dependent dynamic changes in the conformation of the type 1 cholecystokinin receptor affect ligand binding and G protein coupling.
    Harikumar KG; Zhao P; Cary BP; Xu X; Desai AJ; Dong M; Mobbs JI; Toufaily C; Furness SGB; Christopoulos A; Belousoff MJ; Wootten D; Sexton PM; Miller LJ
    PLoS Biol; 2024 Jul; 22(7):e3002673. PubMed ID: 39083706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of Action and Structure-Activity Relationships of Tetracyclic Small Molecules Acting as Universal Positive Allosteric Modulators of the Cholecystokinin Receptor.
    Dengler DG; Harikumar KG; Yen A; Sergienko EA; Miller LJ
    Membranes (Basel); 2023 Jan; 13(2):. PubMed ID: 36837653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.
    Trevaskis JL; Sun C; Athanacio J; D'Souza L; Samant M; Tatarkiewicz K; Griffin PS; Wittmer C; Wang Y; Teng CH; Forood B; Parkes DG; Roth JD
    Diabetes Obes Metab; 2015 Jan; 17(1):61-73. PubMed ID: 25204356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.
    Dong M; Vattelana AM; Lam PC; Orry AJ; Abagyan R; Christopoulos A; Sexton PM; Haines DR; Miller LJ
    Mol Pharmacol; 2015 Jan; 87(1):130-40. PubMed ID: 25319540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process.
    Escrieut C; Gigoux V; Archer E; Verrier S; Maigret B; Behrendt R; Moroder L; Bignon E; Silvente-Poirot S; Pradayrol L; Fourmy D
    J Biol Chem; 2002 Mar; 277(9):7546-55. PubMed ID: 11724786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of Cholecystokinin in the Nutritional Continuum. Physiology and Potential Therapeutics.
    Miller LJ; Harikumar KG; Wootten D; Sexton PM
    Front Endocrinol (Lausanne); 2021; 12():684656. PubMed ID: 34149622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membrane cholesterol affects stimulus-activity coupling in type 1, but not type 2, CCK receptors: use of cell lines with elevated cholesterol.
    Harikumar KG; Potter RM; Patil A; Echeveste V; Miller LJ
    Lipids; 2013 Mar; 48(3):231-44. PubMed ID: 23306829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholecystokinin responsiveness varies across the population dependent on metabolic phenotype.
    Desai AJ; Dong M; Langlais BT; Dueck AC; Miller LJ
    Am J Clin Nutr; 2017 Aug; 106(2):447-456. PubMed ID: 28592602
    [No Abstract]   [Full Text] [Related]  

  • 20. CCK1R agonists: a promising target for the pharmacological treatment of obesity.
    Szewczyk JR; Laudeman C
    Curr Top Med Chem; 2003; 3(8):837-54. PubMed ID: 12678836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.